More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings (-30.4% Growth)
- Ratings (3.8 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/29/16 *Est.)
- Conference (12/1/2015)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 48.92M
Licensing and royalty revenue 203K
Total revenue 49.12M
Research and development
General and administrative 8.75M
Total operating expenses 97.26M
Loss from operations -48.14M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 1.19M
Interest expense -9.23M
Gain (loss) on investments, net
Loss before income tax expense
Income tax expense 0
Net loss -35.78M
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)